ArticleNature nanotechnology2020
Engineering synthetic breath biomarkers for respiratory disease.
Article in Nature nanotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 97 citations in OpenAlex.
- Ingestible probes for breath-based monitoring of drug-metabolizing activity from the microbiome.Science advances · 2026Article
- "Nano-filter"-integrated AIMS with machine learning: direct exhaled breath analysis for lung cancer screening.Chemical science · 2026Article
- Protocol for tumor detection in mice using β-glucuronidase targeted breath analysis.STAR protocols · 2026Article
- Real-time single-particle imaging of functional lungs reveals mosaic-like patterns of aerosol deposition in alveoli.Nature biomedical engineering · 2026Article
- Real-Time Breath Diagnostics: Linking Molecular Pathways, Measurement Technologies, and Clinical Translation.International journal of molecular sciences · 2026Review
- Artificially Engineered Synthetic Biomarkers Revolutionizing Early Diagnosis of Diseases.Molecules (Basel, Switzerland) · 2025Review
- Multidomain Molecular Sensor Devices, Systems, and Algorithms for Improved Physiological Monitoring.Micromachines · 2025Review
- Artificial Intelligence-Powered Nanosensor Platforms for Non-Invasive Breathomic Diagnostics.Nanotechnology, science and applications · 2025Review
- The application of nanoparticles in delivering small RNAs for cancer therapy.Discover oncology · 2024Review
- A breath-based in vitro diagnostic assay for the detection of lower respiratory tract infections.PNAS nexus · 2024Article
- Flavor-switchable scaffold for cultured meat with enhanced aromatic properties.Nature communications · 2024Article
- The therapeutic potential of immunoengineering for systemic autoimmunity.Nature reviews. Rheumatology · 2024Review
- Targeting and monitoring ovarian cancer invasion with an RNAi and peptide delivery system.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Description of an activity-based enzyme biosensor for lung cancer detection.Communications medicine · 2024Article
- Inhalable point-of-care urinary diagnostic platform.Science advances · 2024Article
- A GMR enzymatic assay for quantifying nuclease and peptidase activity.Frontiers in bioengineering and biotechnology · 2024Article
- Ultrasensitive discrimination of volatile organic compounds using a microfluidic silicon SERS artificial intelligence chip.iScience · 2023Article
- Biomolecular sensors for advanced physiological monitoring.Nature reviews bioengineering · 2023Review
- Embracing enzyme promiscuity with activity-based compressed biosensing.Cell reports methods · 2023Article
- Profile of Sangeeta Bhatia.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
Human breath contains many volatile metabolites. However, few breath tests are currently used in the clinic to monitor disease due to bottlenecks in biomarker identification. Here we engineered breath biomarkers for respiratory disease by local delivery of protease-sensing nanoparticles to the lungs. The nanosensors shed volatile reporters upon cleavage by neutrophil elastase, an inflammation-associated protease with elevated activity in lung diseases such as bacterial infection and alpha-1 antitrypsin deficiency. After intrapulmonary delivery into mouse models with acute lung inflammation, the volatile reporters are released and expelled in breath at levels detectable by mass spectrometry. These breath signals can identify diseased mice with high sensitivity as early as 10 min after nanosensor administration. Using these nanosensors, we performed serial breath tests to monitor dynamic changes in neutrophil elastase activity during lung infection and to assess the efficacy of a protease inhibitor therapy targeting neutrophil elastase for the treatment of alpha-1 antitrypsin deficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.